Amifostine is a potent radioprotector of salivary glands in radioiodine therapy: Structural and ultrastructural findings

Strahlentherapie und Onkologie

Volumn 181, Issue 4, 2005, Pages 237-245

  Kutta, Hannes ^a,b   Kampen, Uwe ^a   Sagowski, Christoph ^b   Brenner, Winfried ^a,b   Bohuslavizki, Karl Heinz ^c   Paulsen, Friedrich ^a,d  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Nuclear Medicine Spitalerhof   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Amifostine; High dose radioiodine therapy; Radioprotection; Salivary glands; Thyroid cancer

Indexed keywords

AMIFOSTINE; IODINE 131; RADIOACTIVE IODINE; RADIOPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY SURFACE; CELL NUCLEUS; CELL ORGANELLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; MICROSCOPY; NONHUMAN; PARENCHYMA; PAROTID GLAND; RADIATION PROTECTION; SALIVARY GLAND; SALIVARY GLAND DISEASE; SUBMANDIBULAR GLAND; THYROID CANCER; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AMIFOSTINE; ANIMALS; FEMALE; IODINE RADIOISOTOPES; MODELS, ANIMAL; RABBITS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; SALIVARY GLANDS;

EID: 17844375384     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1353-3     Document Type: Article

References (66)

1. Abot K, Brunk U, Jung B, et al. Morphologic and histochemical studies on the different radiosensitivity of ductular and acinar cells of the rat submandibular gland. Virchows Arch Cell Pathol 1984;45:443-60.
2. Albrecht HH, Creutzig H. Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy. ROFO Fortschr Geb Rontgenstr Nuklearmed 1976;125:546-51.
3. Anne PR. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer [Erratum in: Semin Oncol 2003;30:417]. Semin Oncol 2002;29:Suppl 19:80-3.
4. Baum BJ. Principles of saliva secretion. Ann N Y Acad Sci 1993;694:17-23.
5. 131I). In: Sandler MP, Patton J, Coleman R, et al., eds. Diagnostic nuclear medicine. Baltimore: Williams & Wilkins; 1995:959-89.
6. Bohuslavizki KH, Brenner W, Klutmann S, et al. Implementation and indications for quantitative sialoscintigraphy. Laryngorhinootologie 1997;76:614-24.
7. Bohuslavizki KH, Brenner W, Klutmann S, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 1998;39:1237-42.
8. Bohuslavizki KH, Brenner W, Lassmann S, et al. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun 1996;17:681-6.
9. Bohuslavizki KH, Brenner W, Lassmann S, et al. Quantitative salivary gland scintigraphy - a recommended examination prior to and after radioiodine therapy. Nuklearmedizin 1997;36:103-9.
10. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999;175:Suppl 4:6-12.
11. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. Cancer Biother Radiopharm 1999;14:337-47.
12. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer [Erratum in: J Clin Oncol 2000;18:4110-1]. J Clin Oncol 2000;18:3339-45.
13. Calabro-Jones PM, Fahey RC, Smoluk GD, et al. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 1985;47:23-7.
14. Cherry CP, Glucksman A. Injury and repair following irradiation of salivary glands in male rats. Br J Radiol 1959;32:596-608.
15. Clarke S. Radiojodine therapy of the thyroid. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and therapy. Edinburgh: Churchill Livingstone, 1994:833-45.
16. Denton DA, Nelson JF, Tarjan E. Water and salt intake of wild rabbits (Oryctolagus cunkulus (L)) following dipsogenic stimuli. J Physiol (Lond) 1985;326:285-301.
17. Dreyer JO, Sakuma Y, Seifert G. [Radiation-induced sialadenitis. Stage classification and immunohistology.] Pathologe 1989;10:165-70.
18. Eisbruch A, Kim HM, Terrell JF, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.
19. El-Mofty K, Kahn A. Early membrane injury in lethally irradiated salivary glands. Int J Radiat Biol 1981;39:55-62.
20. English JA. Morphometric effects of irradiation on the salivary glands of rats. J Dent Res 1939;33:656-7.
21. Espinal EG, de Rey BM, Cabrini RL. Radiation effects on submandibular gland of the rat. Stereological and ultrastructural study. Strahlentherapie 1983;159:290-5.
22. Grehn AL, Gustafsson H, Franzen L, et al. Ultrastructural morphometry of parotid acinar cells following fractionated irradiation. Oral Oncol 1997;33:23-8.
23. Gustafsson H, Franzen L, Henriksson R. Regeneration of parotid acinar cells after high radiation doses. A morphological study in rat. Acta Oncol 1995;34:193-7.
24. Helman J, Turner RF, Fox PC, et al. 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl-co-transport system. J Clin Invest 1987;79:1310-3.
25. Horiot JC, Lipinski F, Schraub S, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000;55:233-9.
26. Jellema AP, Langendijk H, Bergenhenegouwen L, et al. The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 2001;59:157-60.
27. Johnstone PA, Peng YP, May BC, et al. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2001;50:353-7.
28. Kouloulias VE, Kouvaris JR, Pissakas G, et al. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol 2004;180:557-62.
29. Kuechler A, Dreidax M, Pigorsch SU, et al. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlenther Onkol 2003;179:493-8.
30. Lotz S, Caselitz J, Tschakert H, et al. Radioprotection of minipig salivary glands by orciprenaline-carbachol. An ultrastructural and semiquantitative light microscopic study. Virchows Arch [A] 1990;417:119-28.
31. McDonald S, Meyerowitz C, Smudzin T, et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994;29:747-54.
32. Menard TW, Izutsu KT, Ensing WY, et al. Radioprotection by WR-2721 of gamma-irradiated rat parotid gland: effect on gland weight and secretion at 8-10 days post irradiation. Int J Radiat Oncol Biol Phys 1984;10:1555-9.
33. Mossman KL. Frequent short-term oral complications of head and neck radiotherapy. Ear Nose Throat J 1994;73:316-20.
34. Muller AC, Pigorsch S, Beyer C, et al. Radioprotective effects of amifostine in vitro and in vivo measured with the comet assay. Strahlenther Onkol 2004;180:517-25.
35. Niibe H, Takahashi I, Miyaishi K, et al. An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors. Nippon Gan Chiryo Gakkai Shi 1985;20:994-1001.
36. Ohnishi ST, Ohnishi ST, Glick JH, et al. In vitro study on the oxidant activities of amifostine (WR-2721). Proc Am Assoc Cancer Res 1992;33:419.
37. Patt HM, Tyree EB, Straube RL, et al. Technical papers. Cystein protection against X irradiation. Science 1949;110:213-4.
38. Pratt NE, Sodicoff M, Liss J, et al. Radioprotection of the rat parotid gland by WR-2721: morphology at 60 days post-irradiation. Int J Radiat Oncol Biol Phys 1980;6:431-5.
39. Rasey JS, Krohn KA, Grunbaum Z, et al. Synthesis, biodistribution and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosp horothioic acid (WR-3689). Radiat Res 1986;106:366-79.
40. Rasey JS, Krohn KA, Menard TW, et al. Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys 1968;12:1487-90.
41. Rasey JS, Spence AM, Badger CC, et al. Specific protection of different normal tissues. Pharmacol Ther 1988;39:33-43.
42. Reiners C, Börner W. Zur Diagnose und Verlaufskontrolle des Schilddrüsenmalignoms. Nuklearmediziner 1980;3:193-210.
43. Reiners C, Eilles C, Eichner R, et al. Speicheldrü senfunktionsszintigraphie zur Verlaufskontrolle bei der Therapie des Schilddrüsen-Karzinoms mit Radiojod. Nuklearmediziner 1980;3:281-6.
44. Romeis B. Mikroskopische Technik. In: Bock P, Hrsg. Färben der Schnitte, 17. Aufl. München: Urban & Schwarzenberg, 1989:34-78.
45. Sagowski C, Wenzel S, Jenicke L, et al. Reducing late toxicity with amifostine in fractionated irradiation of the rat salivary glands. HNO 2002;50:822-8.
46. Sagowski C, Wenzel S, Tesche S, et al. Investigation of radiosialadenitis during fractioned irradiation: sialoscintigraphical and histomorphological findings in rats. Eur Arch Otorhinolaryngol 2003;260:513-7.
47. Schafer W. The effect of single and fractionated doses of selectively applied X-ray irradiation on the histologic structure of the major salivary glands of the rat. J Dent Res 1953;32:796-806.
48. Seifert G, Geier W. Pathology of radiation-induced sialadenitis. Z Laryngol Rhinol Otol 1971;50:376-88.
49. Sholley MM, Pratt NE, Sodicoff M. Cytoplasmic crystalloids in irradiated rat parotid glands. J Oral Pathol 1981;10:192-202.
50. Sholley MM, Sodicoff M, Pratt NE. Early radiation injury in the rat parotid gland. Reaction of acinar cells and vascular endothelium. Lab Invest 1974;31:340-54.
51. Sodicoff M, Conger AD, Pratt NE, et al. Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res 1978;76:172-9.
52. Sodicoff M, Conger AD, Trepper P, et al. Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res 1978;75:317-26.
53. Sodicoff M, Pratt NE, Sholley MM. Ultrastructural radiation injury of rat parotid gland: a histopathologic dose-response study. Radiat Res 1974;58:196-208.
54. Spiegel W, Reiners C, Börner W. Einschränkung der Speicheldrüsenfunktion nach hochdosierter Radiojodtherapie. Nuklearmediziner 1986;9:159-66.
55. Takahashi I, Nagai T, Miyaishi K, et al. Clinical study of the radioprotective effects of amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986;12:935-8.
56. Tarjan E, Denton DA, McKinley MJ, et al. What makes wild rabbits drink? J Physiol (Paris) 1984;79:466-70.
57. Utley JF, Marlowe C, Waddell WJ. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse 1, 2. Radiat Res 1976;68:284-91.
58. Utley JF, Phillips TL, Kane LJ. Protection of normal tissues by WR2721 during fractionated irradiation. Int J Radiat Oncol Biol Phys 1976;1:699-703.
59. Utley JF, Quinn CA, White FC, et al. Protection of normal tissue against late radiation injury by WR-2721. Radiat Res 1981;85:408-15.
60. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 2003;179:385-9.
61. Vacha P, Marx M, Engel A, et al. Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlenther Onkol 1999;175:Suppl 4:18-22.
62. Vissink A, Kalicharan D, S-Gravenmade EJ, et al. Acute irradiation effects on morphology and function of rat submandibular glands. J Oral Pathol Med 1991;20:449-56.
63. Washburn LC, Carlton JE, Hayes RL. Distribution of WR-2721 in normal and malignant tissues of mice and rats bearing solid tumors: dependence on tumor type, drug dose and species. Radiat Res 1974;59:475-83.
64. Wasserman TH, Phillips TL, Ross G, et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin Trials 1981;4:3-6.
65. Weibel ER, Kistler GS, Scherle WF. Practical stereological methods for morphometric cytology. J Cell Biol 1966;30:24-38.
66. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980;3:211-6.